[go: up one dir, main page]

NO961180L - Transdermal device containing (E) -2- (p-fluorophenethyl) -3-fluoroallylamine for the treatment of Alzheimer's disease - Google Patents

Transdermal device containing (E) -2- (p-fluorophenethyl) -3-fluoroallylamine for the treatment of Alzheimer's disease

Info

Publication number
NO961180L
NO961180L NO961180A NO961180A NO961180L NO 961180 L NO961180 L NO 961180L NO 961180 A NO961180 A NO 961180A NO 961180 A NO961180 A NO 961180A NO 961180 L NO961180 L NO 961180L
Authority
NO
Norway
Prior art keywords
fluoroallylamine
fluorophenethyl
disease
alzheimer
treatment
Prior art date
Application number
NO961180A
Other languages
Norwegian (no)
Other versions
NO961180D0 (en
Inventor
Ian Alexander Mcdonald
Michael Gavin Palfreyman
Daniel Hong-Shou Yu
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of NO961180L publication Critical patent/NO961180L/en
Publication of NO961180D0 publication Critical patent/NO961180D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Foreliggende oppfinnelse angår en metode for behandling av Alzheimers sykdom hos en pasient med behov derav, omfattende transdermal administrering til angitte pasient av en terapeutisk effektiv mengde av (E)-2-(p-fluor- fenetyl)-3-fluorallylamin eller et farmasøytisk akseptabelt salt derav. Også tilveiebrakt er en transdermal anordning for administrering av (E)-2- (p-fluorfenetyl)-3-fluorallylamin eller et farmasøytisk akseptabelt salt derav.The present invention relates to a method of treating Alzheimer's disease in a patient in need thereof, comprising transdermal administration to said patient of a therapeutically effective amount of (E) -2- (p-fluorophenethyl) -3-fluoroallylamine or a pharmaceutically acceptable salt thereof. Also provided is a transdermal device for administering (E) -2- (p-fluorophenethyl) -3-fluoroallylamine or a pharmaceutically acceptable salt thereof.

NO961180A 1993-09-24 1996-03-22 Transdermal device containing (E) -2- (p-fluorophenethyl) -3-fluoroallylamine for the treatment of Alzheimer's disease NO961180D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12719093A 1993-09-24 1993-09-24
PCT/US1994/009517 WO1995008325A1 (en) 1993-09-24 1994-08-23 Transdermal device containing (e)-2-(p-fluorophenethyl)-3-fluoroallylamine for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
NO961180L true NO961180L (en) 1996-03-22
NO961180D0 NO961180D0 (en) 1996-03-22

Family

ID=22428772

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961180A NO961180D0 (en) 1993-09-24 1996-03-22 Transdermal device containing (E) -2- (p-fluorophenethyl) -3-fluoroallylamine for the treatment of Alzheimer's disease

Country Status (10)

Country Link
EP (1) EP0720475A1 (en)
JP (1) JPH09505276A (en)
CN (1) CN1131390A (en)
AU (1) AU684545B2 (en)
CA (1) CA2172605A1 (en)
HU (1) HUT75877A (en)
IL (1) IL111017A0 (en)
NO (1) NO961180D0 (en)
WO (1) WO1995008325A1 (en)
ZA (1) ZA947262B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100479405B1 (en) * 2002-05-24 2005-03-30 주식회사 싸이제닉 Cinnamic acid dimers, their preparation and the use thereof for treating neurodegenerative disease
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
JPH07507299A (en) * 1992-05-27 1995-08-10 メレルダウファーマスーティカルズ　インコーポレイテッド Use of (E)-2-(p-fluorophenethyl)-3-fluoroallylamine in the treatment of Alzheimer's disease

Also Published As

Publication number Publication date
ZA947262B (en) 1995-05-23
HU9600725D0 (en) 1996-05-28
HUT75877A (en) 1997-05-28
CA2172605A1 (en) 1995-03-30
CN1131390A (en) 1996-09-18
IL111017A0 (en) 1994-11-28
AU684545B2 (en) 1997-12-18
JPH09505276A (en) 1997-05-27
WO1995008325A1 (en) 1995-03-30
EP0720475A1 (en) 1996-07-10
AU7636494A (en) 1995-04-10
NO961180D0 (en) 1996-03-22

Similar Documents

Publication Publication Date Title
KR930702022A (en) Treatment or prevention of type 1 diabetes by oral administration of insulin
DE69815122D1 (en) SACCHARID-CONTAINING PREPARATIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSES
DE68919358D1 (en) COMPOSITION FOR TREATING SCHIZOPHRENIA.
RU94027680A (en) Parathyroid hormone and raloxifen for bone mass increase, pharmaceutical composition and method of osseous mass increase
BR9306841A (en) Pharmaceutical composition process for providing an antihistamine treatment which does not induce any significant cardiac arrhythmia in a human patient and use of a composition for the manufacture of a medicine for use in an antihistamine treatment
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
FI935847A0 (en) L-DOPA esterkompositioner
DK0833643T3 (en) Formulations of anhydrous monosodium salt of alendronate and their use in the treatment of bone disorders
DE69424777D1 (en) 3,4-DIARYLCHROMANE FOR TREATING DERMATITIS
NO20003313L (en) Therapeutic agents
NO961180L (en) Transdermal device containing (E) -2- (p-fluorophenethyl) -3-fluoroallylamine for the treatment of Alzheimer's disease
NO944524L (en) Use of (E) -2- (p-fluorophenethyl) -3-fluoroallylamine in the treatment of Alzheimer's disease
ATE331523T1 (en) STATIN THERAPY TO IMPROVE MAINTAINING COGNITIVE FUNCTION
DE69233315D1 (en) PHARMACEUTICAL LYSINE CONTAINING POLYPEPTIDE COMPOSITIONS AND METHOD FOR USE THEREOF
DE69800906D1 (en) Use of olanzapine in the manufacture of a medicament for the treatment of cerebral focal ischemia
EA200200559A1 (en) METHOD OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE CONDITIONS
EA199800941A1 (en) THERAPEUTICALLY MEANS CONTAINING OXYGEN ANION-RADICALS AND / OR PRODUCTS OF THEIR SUBSEQUENTAL TURNING AND DIVISION AND THEIR APPLICATION FOR THE TREATMENT OF PARKINSON'S DISEASE
RU94037731A (en) Method for treating multiple sclerosis
MY110416A (en) Composition for the treatment of schizophrenia.
MX9704887A (en) Pharmaceutical compositions for the treatment of depressive disorders.